Finally, early clinical studies with bimekizumab, a dual IL‐17A and IL‐17F neutralizing antibody, have shown rapid and profound clinical responses in psoriasis 21 and PsA 20 patients suggesting an unappreciated role for IL‐17F in addition to IL‐17A in promoting inflammation. This evidence concerns the gene IL17F and psoriasis.